We first established that in vivo hCD19+ B-ALL tumor burden is significantly reduced with treatment with CD19 CAR T cells but not control antigen (EGFRvIII)–targeting CAR T cells (fig. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.